Efficacy of topical cobalt chelate CTC-96 against adenovirus in a cell culture model and against adenovirus keratoconjunctivitis in a rabbit model by Epstein, Seth P et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Ophthalmology
Open Access Research article
Efficacy of topical cobalt chelate CTC-96 against adenovirus in a cell 
culture model and against adenovirus keratoconjunctivitis in a 
rabbit model
Seth P Epstein*†1, Yevgenia Y Pashinsky†1, David Gershon†2, 
Irene Winicov†2, Charlie Srivilasa†1, Katarina J Kristic†1 and Penny A Asbell†1
Address: 1Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York, USA and 2Redox Pharmaceutical Corporation, 
Greenvale, New York, USA
Email: Seth P Epstein* - seth.epstein@mssm.edu; Yevgenia Y Pashinsky - yevgenia.pashinsky@mssm.edu; 
David Gershon - dgershon@redoxpharm.com; Irene Winicov - iwinicov@redoxpharm.com; Charlie Srivilasa - charliesrivilasa7@yahoo.com; 
Katarina J Kristic - KitKat570@hotmail.com; Penny A Asbell - penny.asbell@mssm.edu
* Corresponding author    †Equal contributors
Abstract
Background:  Adenovirus (Ad), associated with significant morbidity, has no topical treatment. A leading CTC
compound (CTC-96), a CoIII chelate, was found to have potent in vitro and in vivo antiviral efficacy against herpes viruses.
In this study CTC-96 is being tested for possible anti-Adenovirus activity.
Methods: The biological anti-adenovirus activity of CTC-96 in concentrations from 5 to 250 ug/ml, was evaluated
initially by viral inactivation (viral exposure to CTC-96 followed by dilution and inoculation of cells), virucidal (viral
exposure to CTC-96 and inoculation of cells without dilution) and antiviral (effect of CTC-96 on previously adsorbed
virus) plaque assays on HeLa (human cervical carcinoma), A549 (human lung carcinoma) and SIRC (rabbit corneal) cells.
After verifying the antiviral activity, New Zealand White rabbits were infected with Ad-5 into: 1) the anterior cul-de-sac
scarifying the conjunctiva (Group "C+"); 2) the anterior cul-de-sac scarifying the conjunctiva and cornea (Group "CC+");
3) the stroma (Group "CI+"). Controls were sham-infected ("C-", "CC-", "CI-"). Other rabbits, after "CC", were treated
for 21 days with: 1) placebo, 9x/day ("-"); 2) CTC-96, 50 ug/ml, 9x/day ("50/9"); CTC-96, 50 ug/ml, 6x/day ("50/6"); CTC-
96, 25 ug/ml, 6x/day ("25/6"). All animals were monitored via examination and plaque assays.
Results:  In  vitro viral inactivation, virucidal and antiviral assays all demonstrated CTC-96 to be effective against
Adenvirus type 5 (ad-5). The in vivo model of Ad keratoconjunctivitis most similar to human disease and producing highest
viral yield was "CC". All eyes (6/6) developed acute conjunctivitis. "CI" yielded more stromal involvement (1/6) and iritis
(5/6), but lower clinical scores (area × severity). Infection via "C" was inconsistent (4/6). Fifty (50) ug/ml was effective
against Ad-5 at 6x, 9x dosings while 25 ug/ml (6x) was only marginally effective.
Conclusion: CTC-96 demonstrated virucidal activity against Ad5 in tissue culture with HeLa, A549 and SIRC cell lines.
Animal Model Development: 1) "CC" produced conjunctival infection with occasional keratitis similar to human disease;
"CI" yielded primarily stromal involvement; 2) "C" consistently produced neither conjunctivitis nor keratitis.
CTC Testing: 1) Conjunctivitis in all eyes; 2) Resolution fastest in "50/9" ("50/9". "50/6" > "25/6" > "-"); 3) Efficacy in "50/
6" was not statistically different than "50/9"; 4) Conjunctival severity was lower in treatment groups then controls; 5) 
Little corneal or intra-ocular changes were noted.
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Background
Adenovirus is the most common external ocular viral
infection worldwide[1]. Although not permanently blind-
ing, ocular adenoviral infections are associated with sig-
nificant patient morbidity, including symptomatic
distress, and corneal changes causing visual disturbances
that can last months to years. About one half of the over
50 serotypes of human adenovirus are known to cause
ocular disease in patients[1]. Currently there are no spe-
cific efficacious antiviral agents for topical or systemic
treatment of Adenoviral infections[2].
The studies of the pathogenesis and treatment of ocular
adenovirus infections have been limited due to the nar-
row host range exhibited by human adenoviruses. It has
been previously determined that one serotype of human
adenovirus, adenovirus type 5 (Ad-5), has the ability to
extend its host range to permit replication in the eyes of
New Zealand rabbits[3,4]. These and other studies have
shown human adenovirus type 5 (Ad-5) to present clini-
cally within 24 to 48 hours of innoculum in rabbits[5]
and last for approximately 16 days post-innoculum
(mean duration of shedding)[5,6].
A number of cobalt complexes (CTC compounds) have
been identified that exhibit potent in vitro and  in vivo
activity against herpes group viruses[7]. Most signifi-
cantly, the mode of action of these novel compounds dif-
fer from currently available antiviral nucleoside analogs
and protease inhibitors[8] (and unpublished data: Redox
Pharmaceutical Corporation). One CTC compound in
particular, CTC-96, has already been shown to exhibit
pronounced efficacy in the topical therapy of HSV-1-
induced epithelial and stromal disease in the rabbit
eye[7].
In this study we evaluate the efficacy of topical CTC-96
against adenovirus infection in tissue culture on both
human and rabbit cell lines as well as against ocular ade-
novirus infection in New Zealand White rabbits.
Methods
Materials
Adenovirus
Human Adenovirus type 5 [9-11] (AD-5) was obtained
from the American Type Culture Collection (VR-5; ATCC,
Manassas, VA) and propagated on human cervical carci-
noma cell monolayers ["HeLa cells" (CCL-2); ATCC, Man-
assas, VA]. Stabilized viral stocks grown in EMEM
[Vitacells Eagle Minimum Essential Medium (30–2003;
ATCC, Manassas, VA)] supplemented with 10% fetal calf
serum (FCS), 100 units/ml penicillin, 0.1 mg/ml strepto-
mycin and 2 mM L-glutamine (all from Sigma chemical
Co., St. Louis, MO) and containing approximately 9 × 108
plaque forming units/ml (pfu/ml) were produced and
stored at -80°C for up to 1 year. Cells were infected at a
Multiplicity of Infection (MOI) of 10. Eyes were infected
with approximately 2 × 107 pfu of virus.
Cells
1) Human cervical carcinoma cells [HeLa cells (CCL-2);
ATCC, Manassas, VA] were grown and maintained in
EMEM supplemented with FCS, penicillin, streptomycin
and L-glutamine as described above.
2) Human lung carcinoma cells [A549 cells (CCL-185);
ATCC, Manassas, VA] were grown and maintained in
Hams F-12 K Medium (30–2004; ATCC, Manassas, VA)
supplemented with 10% fetal calf serum, 100 units/ml
penicillin, 0.1 mg/ml streptomycin and 2 mM L-
glutamine (all from Sigma chemical Co., St. Louis, MO).
3) Rabbit corneal cells [SIRC (CCL-60); ATCC, Manassas,
VA] were grown and maintained in EMEM supplemented
with 10% fetal bovine serum, 100 units/ml penicillin, 0.1
mg/ml streptomycin and 2 mM L-glutamine (all from
Sigma chemical Co., St. Louis, MO).
Pharmaceuticals
Doxovir™, CTC-96 (Figure 1) was synthesized according
to a standard Redox Pharmaceutical Corporation proce-
dure[12]. CTC-96 solution (stable in aqueous solutions at
4°C for >6 months and for several weeks at 37°C) was
prepared from crystalline compound which is completely
stable for over 2.5 years when stored desiccated at 0°C.
The structure was confirmed by the manufacturer utilizing
1H and 13C nuclear magnetic resonance spectroscopy,
mass spectrometry, and elemental analysis[12]. Using
these techniques, purity was determined to be ≥ 99%,
with no detectable impurities[12]. Prior to use, drug con-
centrations in all CTC-96 solutions were confirmed by
HPLC against an independently prepared CTC-96 stand-
ard. The activity of the drug solutions was confirmed in an
The general structure of Doxovir™ (CTC-96) Figure 1
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anti-Herpes Simplex-1 assay[9]. Formulations of this sta-
bilized active compound at the appropriate concentra-
tions were prepared, filter-sterilized and supplied by the
manufacturer. Samples were stored refrigerated and pro-
tected from light prior to use.
Animals
New Zealand White Rabbits weighing 4–5 pounds were
purchased from H.A.R.E. Industries (Hewitt, NJ). Animals
were designated both SPF (specific pathogen free) and
VAF (viral antigen free) and were handled in accordance
with NIH guidelines. At the conclusion of each experi-
ment, the rabbits were euthanized by pentobarbital injec-
tion (Sleepaway, Fort Dodge Labs, Fort Dodge, IA).
Rabbits were housed in the pathogen containment area
(BSL-2) of the Mount Sinai Medical Center Animal Facil-
ity. Newly received animals were allowed to acclimate to
the facility and to daily handling for one week prior to
infection. All rabbits were examined to verify no clinical
or culture evidence of viral disease (slit lamp biomicros-
copy and viral cultures of corneal swabs followed by
standardized plaque assays).
Procedures
I. In vitro studies
A. In vitro viral inactivation assays (direct drug-virus {high titer} 
neutralization with post-neutralization CTC dilution)
Varying concentrations of CTC-96 or placebo were mixed
with concentrated human Adenovirus type 5 (Ad5; 1.75 ×
107 pfu) and incubated at 37°C for 60 minutes (min)
under atmospheric conditions. Aliquots of the virus/drug
suspension were then diluted 500 fold and plated in trip-
licate on aspirated HeLa, A549 and SIRC cell monolayers
to initiate infection (6–8 × 105 cells/cm2 in T-25 culture
flasks containing 9.9 mls fresh culture medium giving a
total volume of 10 mls with an MOI of 10). The low final
concentration of the CTC-96 (1:500) has no inhibitory
effect on Adenovirus type 5 growth. All cell lines were
grown and maintained in their appropriate medium.
The cell monolayers, having been infected with the virus,
were incubated for 24 hours (hr) at 37°C and 5% CO2
and then washed, scraped, sonicated, centrifuged and the
supernatant serially diluted. These serial dilutions were
plated onto indicator HeLa, A549 and SIRC cell monolay-
ers and adsorbed for 60 min. The supernatant was then
aspirated and a methylcellulose overlay placed over the
cells which were then incubated at 37°C. Due to differ-
ences in replication rates of the Adenovirus in the various
cell lines, HeLa cells were incubated for 3 days, A549 cells
for 5 days and the SIRC cells for 7 days. All were counter-
stained with 1% methylene blue, allowed to dry and the
plaques counted under a phase contrast microscope in a
masked fashion.
B. In vitro virucidal assays (direct drug-virus neutralization without 
post-neutralization CTC dilution)
Varying concentrations of CTC-96 or placebo were mixed
with concentrated human Adenovirus type 5 (Ad5; 1.75 ×
107 pfu) and incubated at 37°C for 60 minutes (min).
Media of the HeLa, A549 and SIRC cell monolayers (at
80% confluency) was decanted and replaced with the
above suspension. These cell monolayers, having now
been infected with the virus (6–8 × 105 cells/cm2 in T-25
culture flasks containing 9.9 mls fresh culture medium
giving a total volume of 10 mls with an MOI of 10), were
incubated for 24 hours (hr) at 37°C and 5% CO2 in
medium containing CTC-96 at the indicated concentra-
tions and then washed, scraped, sonicated, centrifuged
and the supernatant serially diluted.
The serial dilutions were then plated onto indicator HeLa,
A549 and SIRC cell monolayers and adsorbed for 60 min
as described above. The supernatant was then aspirated
and a methylcellulose overlay placed over the cells which
were then incubated at 37°C. All were counterstained
with 1% methylene blue, allowed to dry and the plaques
counted under a phase contrast microscope in a masked
fashion.
C. In vitro antiviral activity assays (effect of CTC-96 on virus 
previously adsorbed onto cells)
Adenovirus type 5 (1.75 × 107 pfu) was adsorbed onto
preconfluent HeLa, A549 and SIRC cell monolayers for 60
min at 37°C. Various concentrations of CTC-96 or pla-
cebo in medium were then added to the culture and the
monolayers were subsequently incubated for 24 hr at
37°C and 5% CO2. Monolayers were then washed,
scraped, sonicated, centrifuged, the supernatants serially
diluted and ultimately stained and the plaques counted as
described above under the section for the viral inactiva-
tion assay.
D. Procedure
The biological anti-adenovirus activity of freshly solubi-
lized CTC-96 was evaluated by the standard antiviral,
virucidal and antiviral plaque reduction assays as
described above. Seven concentrations of CTC-96 were
used with each cell line and in each assay: 0, 5, 10, 25, 50,
100 and 250 ug/ml. Both negative (0 ug/ml CTC-96, no
Ad-5) and positive [0 ug/ml CTC-96, addition of Ad-5
(MOI = 10)] controls were included. All were diluted in
the appropriate medium for each of the cell lines.
E. Data analysis
All clinical and virus recovery data were analyzed for sta-
tistical differences, utilizing the mean ± standard devia-
tion for each of the various groups in computer-generated
two-tailed bivariant Student's t tests (GB-STAT, New Eng-
land Software, Inc., College Station, TX, U.S.A.; SAS, SASBMC Ophthalmology 2006, 6:22 http://www.biomedcentral.com/1471-2415/6/22
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Institute Inc., Cary, NC, U.S.A.; and SPSS, SPSS Inc., Chi-
cago, IL, U.S.A.)[13,14]. Individual Fisher exact tests were
also performed (GB-STAT, SAS and SPSS)[13,14], as well
as an overall chi-squared analysis (GB-STAT, SAS and
SPSS)[13,14] and a correlation coefficient[13,14]. Two-
tailed significance was established at a confidence level of
0.05 ≤ P ≤ 0.95.
II. Animal studies
A. Methods of viral infection (6 groups)
1. Experimental
a. Installation of 20 ul containing 4 × 107 pfu Ad-5 into
the anterior cul-de-sac and scarifying the conjunctiva (4
scratches) with a 25-gauge needle (Group "C+": 8 eyes).
b. Installation of 20 ul containing 4 × 107 pfu Ad-5 into
the anterior cul-de-sac and scarifying the conjunctiva and
cornea (8 scratches: 4 to conjunctiva, 4 to cornea) with a
25-gauge needle (Group "CC+": 8 eyes).
c. Injection of 20 ul containing 4 × 107 pfu Ad-5 into the
corneal stroma with a 25-gauge needle (Group "CI+": 8
eyes).
Sham-infected animals of all groups were attempted as
controls:
2. Controls
a. Installation of 20 ul containing sterile HeLa media
[Eagles Minimum Essential Medium (EMEM; ATCC, Man-
assas, VA) + 10% fetal calf serum (Hyclone, Logan, UT) +
1% penicillin/streptomycin (Sigma Chemical Company,
St. Louis, MO) + 1% l-glutamine (Sigma Chemical Com-
pany, St. Louis, MO)] into the anterior cul-de-sac and scar-
ifying the conjunctiva (4 scratches) with a 25-gauge
needle (Group "C-": 8 eyes).
b. Installation of 20 ul containing sterile HeLa media into
the anterior cul-de-sac and scarifying the conjunctiva and
cornea (8 scratches: 4 to conjunctiva, 4 to cornea) with a
25-gauge needle (Group "CC-": 8 eyes).
c. Injection of 20 ul containing HeLa media into the cor-
neal stroma with a 25-gauge needle (Group "CI-": 8 eyes).
3. Procedure
The eyes were randomly sorted into groups, examined by
a masked observer (ophthalmologist) by slit-lamp biom-
icroscopy [Days 1 (preinfection), 3, 5, 7, 10, 12, 15, 17,
19, 23, 26, 30 post-infection (pi)] and scored using the
grading system for rabbit conjunctival disease (Table 1)
derived from that originally described by Wander et al[15]
for herpes simplex virus (HSV).
Corneal swabs (Viral Culturettes, Baxter, Deerfield, IL)
were taken for viral plaque assay twice per week [Days 1
(preinfection), 3, 5, 7, 10, 12, 15, 17, 19, 23, 26 and 30
pi]. Briefly, sterile culturettes were gently swabbed across
the corneas (one per cornea) and the swabbed culturettes
immediately eluted with 0.5 ml of Hanks balanced salt
solution and serial 1:10 dilutions prepared for virus
assays. Neither sterile culturettes nor cultures received any
other manipulation. Culturettes were not frozen prior to
titration. Plaque assays were performed in triplicate to
ensure reproducibility.
B. CTC testing
1. Infection
The conjunctivae and corneas were infected with 20 ul
containing 4 × 107 pfu of virus into the anterior cul-de-sac
and then scarified with a 25-gauge needle (8 scratches: 4
to conjunctiva, 4 to cornea: exactly as in Group "CC+"
above)[16].
2. Treatment Groups (4 groups)
The animals were sorted into treatment groups of
matched disease severities on day 7 post-infection, when
all eyes showed disease signs, averaging 2–3, suggestive of
acute conjunctivitis.
Grouped animals were treated, both eyes identically, with
instillation of a 20 ul drop per eye of:
a. Placebo treatment (formulation without active ingredi-
ent), nine times per day [9x/day ("-"): 2 eyes],
b. CTC-96, 50 ug/ml, 9x/day ("50/9"), 2 eyes,
c. CTC-96, 50 ug/ml, six times per day [6x/day ("50/6")],
2 eyes,
or
d. CTC-96, 25 ug/ml, 6x/day ("25/6"), 2 eyes.
The formulation consisted of: 45 mg/ml mannitol, 60 ug/
ml benzalkonium chloride, 2 mg/ml 2-methylimidazole
in aqueous solution (pH 7.4). Drug treatments were
spread out over each day (7:30 a.m. to 9:30 p.m.), for 21
days of treatment (both eyes of each animal treated iden-
tically).
3. ProcedureBMC Ophthalmology 2006, 6:22 http://www.biomedcentral.com/1471-2415/6/22
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The eyes were examined in a masked fashion by an oph-
thalmologist. They were graded clinically (Table 1) and
corneal swabs (Viral Culturettes, Baxter, Deerfield, IL)
were taken for viral plaque assay twice per week [Days 7
(pretreatment on day of treatment initiation), 10, 14, 17,
20, 25, 28, 31, 35 and 38 post-infection (pi; Days 1, 3, 7,
10, 13, 18, 21, 24, 28 and 31 post-treatment initiation
(pti)]. Briefly, sterile culturettes were gently swabbed
across the corneas (one per cornea) and the swabbed cul-
turettes immediately eluted with 0.5 ml of Hanks bal-
anced salt solution and serial 1:10 dilutions prepared for
virus assays. Neither sterile culturettes nor cultures
received any other manipulation. Culturettes were not fro-
zen prior to titration. Plaque assays were performed in
triplicate to ensure reproducibility.
a. Standardized Viral Plaque Assays
Titers of active virions of adenovirus, scored on preconflu-
ent HeLa cell culture monolayers and expressed as plaque
forming units (pfus) were determined according to estab-
lished procedures[17]. Monolayers were grown and main-
tained in "HeLa media" [Vitacell= s Eagle Minimum
Essential Medium (30–2003; ATCC, Manassas, VA) + 10%
fetal calf serum + 1% penicillin/streptomycin + 1% l-
glutamine (all from Sigma chemical Co., St. Louis, MO).
Three days after inoculation (at 37°C and 5% CO2) with
serial ten-fold dilutions of analyte, plaques had formed
and the plates were stained with 1% methylene blue,
allowed to dry and the plaques counted under a phase
contrast microscope in a masked fashion in that the exam-
iner had no knowledge of the treatment protocol for the
individual animals. The animals were examined in a
unique, random order for each examination.
b. Ocular Grading System
Clinical disease was divided up into: conjunctival, corneal
epithelial and stromal disease and iritis. Corneal epithe-
lial disease was subdivided into SPK, epithelial adenovi-
rus symptoms, pannus, and epithelial defect. Stromal
disease was subdivided into: edema, melting, neovascu-
larization and infiltrate. Both the area and severity of each
subdivision was graded individually from 0 to +4. Area of
involvement was represented in increasing amounts of
25% (0 = "normal cornea", +1 = ≤ 25%, +2 = >25%, ≤
50%, +3 = > 50%, ≤ 75%, +4 = > 75%, ≤ 100%). While
severity of each subdivision was graded while the severity
of each subdivision was individually graded from 0 (nor-
mal cornea) to +4 (severe).
c. Data Analysis
aa. Clinical Data
While conjunctival, corneal epithelial, stromal and iritis
data was collected clinically, for simplicity only conjunc-
tival data was graphed as other findings were insignificant
(≈0). Clinical scores (area × severity) were calculated and
utilized for all statistical calculations.
Non parametric methods of statistical analysis were used
because disease severity is graded by assigning numerical
scores[15,16] to observed lesions. The arithmetic means
of such arbitrarily scaled scores should not be analyzed by
parametic methods such as the student's t test. Instead,
rank medians[18,19], a Wilcoxson-Mann-Whitney rank-
sum test[19,20], as well as both Spearman[19,21] and
Kendall[19,22] rank correlations, as per standard non-
parametric statistics, were used for analysis of the rank
nonparametric assigned scores because non-parametric
statistical techniques permit evaluation of significance of
chemotherapeutic efficacies when measured by changes
in severity of disease signs. The results presented were con-
sidered significant at a rank median of ≤ 0.05 units.
bb. Virus Recovery Data
Viral titers (per ml) were analyzed for statistical differ-
ences, utilizing the mean ± standard deviation for each of
the various groups in computer-generated two-tailed
bivariant Student's t tests[13,14] (GB-STAT, New England
Software, Inc., College Station, TX, U.S.A.; SAS, SAS Insti-
tute Inc., Cary, NC, U.S.A.; and SPSS, SPSS Inc., Chicago,
IL, U.S.A.)[13,14] at all time points. Individual Fisher
exact tests[13,14] were also performed, as well as an over-
all chi-squared analysis[13,14] and a correlation coeffi-
cient[13,14]. Two-tailed significance was established at a
confidence level of 0.05 ≥ P ≥ 0.95.
Results
I. In vitro studies
Viral inactivation, virucidal and antiviral efficacy studies
in tissue culture demonstrated CTC-96 to be effective
against human Adenovirus type 5 in a dose-dependent
fashion (Tables 1 and 2). CTC-96 at doses ≥ 50 ug/ml
shows high levels of antiviral efficacy in the viral inactiva-
tion, virucidal and antiviral (post-infection) models,
against human Adenovirus type 5 in all three cell lines
used. The standardized Viral Inactivation, Virucidal and
Antiviral assays showed viral yield to be almost zero at a
concentration of 50 ug/ml and virtually zero at 100 ug/ml
for the two human cell types [HeLa & A549; virucidal and
antiviral: 6.67 × 101 pfu/flask (8-fold inactivation of viri-
ons: Table 1)]. In rabbit corneal cells (SIRC), viral yield
reached undetectable levels even at 50 ug/ml (Tables 1
and 2). There was a precipitous, dose dependent inhibi-
tion between 25 and 50 ug/ml of CTC-96 and a modest
effect at still lower concentrations (i.e. 2.47 × 109 pfu at 10BMC Ophthalmology 2006, 6:22 http://www.biomedcentral.com/1471-2415/6/22
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ug/ml and 1.17 × 109 pfu at 25 ug/ml; Table 1) demon-
strating, as previously mentioned, dose dependence.
In all assays, the compound exhibited consistently effec-
tive antiviral effects against adenoviral infections in HeLa,
A549 and SIRC cell types (Tables 1 and 2) and statistically
significant differences were observed in all assays (Viral
Inactivation, Virucidal and Antiviral) between each of the
three cell types. These differences were fairly constant for
the various cell lines. For example, A549 viral titers were
consistently approximately half (i.e. approx 50%) those of
the identical assays run on HeLa cells (see Table 1), while
the titers of the rabbit corneal cells (SIRC) were consist-
ently one sixth (i.e. approx 17%) those of the identical
assays run on human lung carcinoma (A549; see Table 1).
Table 2: ED 50s & 90s of Doxovir™ to Adenovirus Type 5. Effective dose (ED) 50s and 90s of Doxovir™ (CTC-96) against Adenovirus 
type 5 in HeLa (human cervical carcinoma), A549 (human cervical carcinoma) and SIRC (rabbit corneal) cells during Virucidal, 
Antiviral and Viral Inactivation assays.
(MIC 50 (µg/ml) (MIC 90 (µg/ml)
HeLa (human cervical carcinoma) Virucidal 33.0 ± 6.9 46.6 ± 9.7
Antiviral 4.5 ± 0.1 21.8 ± 1.2
Viral Inactivation 16.5 ± 2.5 43.0 ± 1.3
A549 (human lung carcinoma) Virucidal 31.7 ± 1.9 46.3 ± 2.6
Antiviral 4.7 ± 0.2 20.8 ± 1.9
Viral Inactivation 4.2 ± 1.1 37.5 ± 6.5
SIRC (rabbit cornea) Virucidal 13.6 ± 2.3 22.7 ± 3.5
Antiviral 27.3 ± 8.3 45.5 ± 1.6
Viral Inactivation 13.1 ± 2.9 23.9 ± 4.9
Table 1: In VitroPlaque Assays. Human Adenovirus type 5 (Ad-5) viral titers [plaque forming units (pfu)/preliminary flask] in Virucidal, 
Antiviral and Viral Inactivation assays in HeLa (human cervical carcinoma), A549 (human cervical carcinoma) and SIRC (rabbit 
corneal) cells.
Com-pound Cell Line Conc. Virucidal Antiviral Viral Inactivation
Average Standard 
Deviation
Average Standard 
Deviation
Average Standard 
Deviation
(µg/ml) (PFU) (PFU) (PFU) (PFU) (PFU) (PFU)
Negative Control (None) HeLa 0 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0
A549 0 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0
SIRC 0 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0
CTC-96 HeLa (human cervix) 0 5.00 × 109 ±0 . 0 0  ×  1 0 0 4.00 × 1010 ±0 . 0 0  ×  1 0 0 5.33 × 109 ±5 . 7 7  ×  1 0 8
5 4.67 × 109 ±5 . 7 7  ×  1 0 8 1.77 × 1010 ±5 . 7 7  ×  1 0 8 4.67 × 109 ±5 . 7 7  ×  1 0 8
10 3.67 × 109 ±5 . 7 7  ×  1 0 8 1.33 × 1010 ±5 . 7 7  ×  1 0 8 2.47 × 109 ±5 . 7 7  ×  1 0 7
25 3.67 × 109 ±5 . 7 7  ×  1 0 8 1.47 × 109 ±5 . 7 7  ×  1 0 7 1.17 × 109 ±5 . 7 7  ×  1 0 7
50 6.67 × 101 ±5 . 7 7  ×  1 0 1 1.00 × 102 ±1 . 0 0  ×  1 0 2 3.33 × 101 ±5 . 7 7  ×  1 0 1
100 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0
250 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0
A549 (human lung) 0 3.07 × 109 ±5 . 7 7  ×  1 0 7 2.47 × 1010 ±5 . 7 7  ×  1 0 8 3.33E+09 ± 5.77 × 108
5 2.77 × 109 ±5 . 7 7  ×  1 0 7 1.17 × 1010 ±5 . 7 7  ×  1 0 8 2.77E+09 ± 5.77 × 107
10 2.27 × 109 ±5 . 7 7  ×  1 0 7 8.67 × 109 ±5 . 7 7  ×  1 0 8 1.47E+09 ± 5.77 × 107
25 2.10 × 109 ±0 . 0 0  ×  1 0 0 9.33 × 107 ±5 . 7 7  ×  1 0 6 6.67E+08 ± 5.77 × 107
50 6.67 × 101 ±5 . 7 7  ×  1 0 1 6.67 × 101 ±5 . 7 7  ×  1 0 1 3.33E+01 ± 5.77 × 101
100 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0
250 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0
SIRC (rabbit cornea) 0 5.67 × 108 ±5 . 7 7  ×  1 0 7 3.67 × 109 ±5 . 7 7  ×  1 0 8 5.33 × 108 ±5 . 7 7  ×  1 0 7
5 4.67 × 108 ±5 . 7 7  ×  1 0 7 3.67 × 109 ±5 . 7 7  ×  1 0 8 3.00 × 108 ±5 . 7 7  ×  1 0 7
10 4.33 × 108 ±5 . 7 7  ×  1 0 7 3.10 × 109 ±1 . 0 0  ×  1 0 8 3.33 × 108 ±5 . 7 7  ×  1 0 7
25 5.77 × 107 ±0 . 0 0  ×  1 0 0 2.03 × 109 ±5 . 7 7  ×  1 0 7 1.00 × 107 ±0 . 0 0  ×  1 0 0
50 3.33 × 101 ±5 . 7 7  ×  1 0 1 3.33 × 101 ±5 . 7 7  ×  1 0 1 0.00 × 100 ±0 . 0 0  ×  1 0 0
100 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0
250 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0 0.00 × 100 ±0 . 0 0  ×  1 0 0BMC Ophthalmology 2006, 6:22 http://www.biomedcentral.com/1471-2415/6/22
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II. Animal studies
A. Methods of viral infection
Clinical biomicroscopic examination and standardized
antiviral plaque assay showed rabbit ocular infection with
human Adenvirus type 5 via the corneal and conjunctival
scarification method (Group "CC") produced an acute
conjunctivitis (6/6 eyes) with occasional keratitis that
appeared similar to human disease (Figure 2). The CI
group produced lower conjunctival clinical scores than
the CC group, but did yield rare stromal involvement (1/
6 eyes) and greater iritis (5/6 eyes; Figure 2). Infection via
the conjunctival scarification method (Group "C+")
yielded conjunctivitis in 4/6 eyes (Figure 2). None of the
control animals ("C-", "CC-", "CI-") developed any signs
of conjunctivitis or keratitis.
The plaque assays matched the clinical disease (Figure 3).
The corneal and conjunctival scarification group (CC)
developed viral titers by day 3 post-infection comparable
to those of the corneal injection group (CI; Figure 3).
Bearing this out, the conjunctival scarification group (C)
developed viral titers significantly less (other than on day
5 p.i.) than either of the other two groups (Figure 3).
While viral clearance was achieved in the conjunctival
scarification group (C) at day 12 p.i., it was not achieved
until day 15 p.i. for CC or 17 for CI (Figure 3) in the other
two.
Since the corneal and conjunctival scarification group
(CC) consistently developed acute conjunctivitis similar
to human disease this model was chosen to evaluate the
CTC treatment for acute adenovirus conjunctivitis.
B. CTC testing
Both clinical biomicroscopic examination and standard-
ized antiviral plaque assay showed CTC-96 at all concen-
trations and frequencies tested was effective against ocular
disease caused by adenovirus type 5. The majority of clin-
ical signs of infection were in the conjunctiva, with only
minimal and occasional signs observable in the corneal
epithelium and/or stroma.
Clinically, placebo-treated eyes initially showed a gradual
worsening in clinical scores (up to a rank sum of 8) until
Day 14 pi (Day 7 pti), after which they slowly resolved for
another 3 weeks (Figure 4).
Animals treated with CTC-96 at 50 ug/ml, showed a
steady improvement in clinical scores (Figure 4) in both
of the dosing frequencies evaluated (9x/day and 6x/day).
No adverse events were noted in any of the eyes and the
clinical scores did not exceed 4–5 with these treatments.
Statistical significance as compared to the placebo group
was achieved for [Days 10, 14, 17, 20, 25 and 28 pi (Days
1, 3, 7, 10, 13, 18 and 21 pti; 50/9: Wilcoxin-Mann: p ≤
0.03; 50/6: Wilcoxin-Mann: p ≤ 0.04). The marginal effect
that the increased frequency of 9x/day appeared to have
had over that of 6x/day was not statistically significant.
Clinically, conjunctivae of both frequencies (9x/day and
Averages ± standard deviations of infectious virus titers  [plaque forming units (pfu)/ml] of model development ani- mals by group Figure 3
Averages ± standard deviations of infectious virus titers 
[plaque forming units (pfu)/ml] of model development ani-
mals by group. Group "C": corneal infection, conjunctival 
scarification; Group "CC": corneal infection, conjunctival and 
corneal scarification; Group "CI": stromal infection. "+" ani-
mals ("C+", "CC+", "CI+") were infected with active virus, "-" 
were sham-infected ("C-", "CC-", "CI-").
Pearson rank sum medians ± nonparametric equivalents of  standard deviation of conjunctival clinical scores (clinical  score = area × severity) of conjunctivae of model develop- ment animals by group Figure 2
Pearson rank sum medians ± nonparametric equivalents of 
standard deviation of conjunctival clinical scores (clinical 
score = area × severity) of conjunctivae of model develop-
ment animals by group. Group "C": corneal infection, con-
junctival scarification; Group "CC": corneal infection, 
conjunctival and corneal scarification; Group "CI": stromal 
infection. "+" animals ("C+", "CC+", "CI+") were infected 
with active virus, "-" were sham-infected ("C-", "CC-", "CI-").
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6x/day: Figure 4) of CTC-96 at 50 ug/ml resolved on Days
28 – 31 pi (Days 21–24 pti) and were statistically indistin-
guishable in clinical severity until resolution (Wilcoxin-
Mann: p ≥ 0.80).
In all cases, CTC-96 at 25 ug/ml, 6x/day, was effective
against human adenovirus type 5 as compared to sham-
treated eyes. Although only statistically significant at Days
10, 14 and 20 pi (Days 3, 7 and 13 pti), while the placebo-
treated eyes were still visibly resolving clinically at Day 38
pi (the last exam day: Day31 pti), CTC-96 at 25 ug/ml, 6x/
day, had visibly resolved by Day 35 (Day 28 pti; Figure 4).
The clinical observations in which placebo-treated eyes
initially showed a gradual worsening, after which they
slowly resolved, was confirmed by the plaque assays (Fig-
ure 5)]. Viral clearance was not achieved until Day 28 pi
(Day 21 pti; Figure 5) in the placebo-treated eyes.
The viral plaque assays also demonstrated that CTC-96 at
50 ug/ml in both of the dosing frequencies evaluated (9x/
day and 6x/day), eliminated virus by Day 20 pi (Day 13
pti; Figure 5), whereas 25 ug/ml, 6x/day was significantly
less effective [t test: p ≥ 0.01 (50 ug/ml, 9x/d > 50 ug/ml,
6x/d: p ≥ 0.01; 25 ug/ml: p = 0.02)]. While viral clearance
occurred at Day 20 pi (Day 13 pti) at both of the dosage
frequencies of 50 ug/ml (Figure 5), viral titers were already
significantly lowered (ie there was a significant difference
between the two) at Day 10 pi (Day 3 pti) as compared to
that of the control [t test: p = 0.02 (50 ug/ml, 9x/d < 50
ug/ml, 6x/d)].
At 25 ug/ml, 6x/day, CTC-96 was effective against human
adenovirus type 5 as compared to placebo-treated eyes
and viral clearance in this group was not achieved until
Day 28 pi (Day 21 pti), as compared to Day 31 pi (Day 24
pti) in the placebo-treated eyes (Figure 5). Thus, in con-
clusion, although some therapeutic effects of CTC-96 at
25 ug/ml are observed at 6x/day, it was considerably infe-
rior to 50 ug/ml (50 ug/ml, 9x/day. 50 ug/ml, 6x/day >>
25 ug/ml, 6x/day).
Discussion
This study demonstrates that the cobalt chelate CTC-96
(designated Doxovir™) is an effective antiviral agent
against human Adenovirus type 5 both in cell culture and
in rabbits. Adenovirus type 5 infection of human and rab-
bits cells was effectively treated by CTC-96 and primary
ocular human adenovirus type 5-induced conjunctivitis in
a New Zealand White rabbit model was effectively treated
by topical administration with CTC-96. Treatment consid-
erably reduced both disease severity and corneal surface
viral titers, significantly shortening the course of the dis-
ease and the symptoms in parallel. The data presented
here indicate that against Ad-5, six (6) daily applications
of CTC-96 at 50 ug/ml are approximately as effective as
nine (9) daily applications. Six (6) daily applications of
25 ug/ml CTC-96 are inferior to either of the other two,
but significantly better than placebo. It is most likely that
this demonstrates a dose responsiveness, although the
Averages ± standard deviations of plaque assay viral titers  [plaque forming units (pfu)/ml] of CTC-treated animals by  group Figure 5
Averages ± standard deviations of plaque assay viral titers 
[plaque forming units (pfu)/ml] of CTC-treated animals by 
group. Placebo (squares, solid line); 50 ug/ml, 9x/day ["50/9" 
(triangles, dotted line)]; 50 ug/ml, 6x/day ["50/6" (diamonds, 
mixed solid/dotted line)]; 258 ug/ml, 6x/day ["25/6" (aster-
isks/circles, dashed line)].
Pearson rank sum medians ± nonparametric equivalents of  standard deviations of conjunctival clinical scores (clinical  score = area × severity) of CTC-treated animals by group Figure 4
Pearson rank sum medians ± nonparametric equivalents of 
standard deviations of conjunctival clinical scores (clinical 
score = area × severity) of CTC-treated animals by group. 
Placebo (squares, solid line); 50 ug/ml, 9x/day ["50/9" (trian-
gles, dotted line)]; 50 ug/ml, 6x/day ["50/6" (diamonds, mixed 
solid/dotted line)]; 258 ug/ml, 6x/day ["25/6" (asterisks/cir-
cles, dashed line)].
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possibility of a low sample population size producing the
observed effect cannot be entirely discounted.
Currently there are no specific antiviral agents for topical
or systemic treatment of adenoviral infections[2]. Antivi-
ral agents active against HSV and interferons have been
used in the treatment of Adenovirus infections with only
limited effect[23,24]. Thus far, previous recent in vitroex-
periments with the cobalt chelate CTC-96, in addition to
showing strong anti-herpes simplex efficacy[7,8], have
demonstrated anti-human adenovirus type 5 efficacy of
CTC-96[5,6]. In addition, newer nucleoside analogs have
recently been found to exhibit some inhibitory activity
against Adenovirus in vitroand in vivo [24-27].
Topical cidofovir, a nucleoside analog, was shown to be
an effective topical agent against against adenovirus in
non-human systems and may have some effect in
man[28,29], however it has proven to be too toxic in
human eyes. Interestingly, despite the relatively short
experience with the drug, cidofovir-resistant adenovirus
variants have already been observed[30]. Since CTC-96
has been found to have a very different mechanism of
action than nucleoside analogs, it has been shown to be
effective against drug-resistant mutants of herpes viruses
(unpublished results: Redox Pharmaceutical Corpora-
tion).
In the past it has been difficult to define a reliable animal
model of adenovirus ocular disease. For the most part pre-
vious studies of the pathogenesis and treatment of ocular
adenovirus infections have been limited by the narrow
host range exhibited by human adenoviruses. About half
of the greater than 50 serotypes of human adenovirus are
known to cause ocular disease in humans [3-6] yet only
three have been previously found to have the ability to
extend their host range to permit replication in the eyes of
New Zealand rabbits [3-6].
We developed a simple, reliable method of inducing ade-
novirus infection that mimics human disease using a rab-
bit model. Previous animal models of adenovirus
employed the injection of active virus into the corneal
stroma first described by Gordon, et al[3]. This "corneal
injection method" is technically difficult and neither
mimics nor even approximates the usual routes of human
infection. For this reason, we evaluated three (3) methods
of infecting the ocular surface with adenovirus to deter-
mine which most mimicked human adenovirus ocular
disease, and was repeatable and easy to create: 1) the
"conjunctival scarification method" involving the instal-
lation of 20 ul containing 2 × 107 pfu Ad-5 into the ante-
rior cul-de-sac with a scarified conjunctiva (Group "C+");
2) the "corneal and conjunctival scarification method"
involving the installation of 20 ul containing 2 × 107 pfu
Ad-5 into the anterior cul-de-sac after both the conjunc-
tiva and cornea were scarified (Group "CC+"); and 3) the
"corneal injection method" involving the intrastromal
injection of 20 ul containing 2 × 107 pfu of Ad-5 into the
cornea (Group "CI+"). Concurrent controls with conjunc-
tival scarification (Group "C-") or corneal and conjuncti-
val scarification (Group "CC-") did not develop acute
conjunctivitis or keratitis as evaluated by a masked
observer.
When compared both clinically and via the quantification
of viral titers (standardized plaque assay), infection via
the corneal and conjunctival scarification method (Group
"CC") produced a conjunctival infection with occasional
keratitis most similar to human disease. It was easier and
more reliable than the corneal injection (Group "CI") or
the conjunctival scarification methods. The corneal injec-
tion method utilized by other authors[3,4] yields more
stromal involvement than the "CC" group ["CI": 2/6 eyes
(33%) versus "CC": 0/6 eyes (0%)] but is more difficult to
create.
The results presented here demonstrate that adenovirus
infection via the corneal and conjunctival scarification
method (Group "CC") produced the best rabbit model to
study conjunctival infection, while the corneal injection
method (Group "CI") produced more stromal involve-
ment and iritis making it the model of choice to study
stromal disease and iritis.
As previously mentioned, a number of cobalt complexes
(CTC compounds) were found to exhibit potent in vitro
and in vivo activity against herpes group viruses [7]. The
CTC compound in this study, CTC-96, has already been
shown to exhibit pronounced efficacy in the treatment of
HSV-1 in cell culture studies on vero cells[7] as well as in
topical therapy of HSV-1-induced epithelial and stromal
disease in the rabbit eye[7]. Safety data and toxicity stud-
ies have shown the agent to exhibit minimal signs of tox-
icity and to not be readily absorbed during topical
application[7,8] (and unpublished data: Redox Pharma-
ceutical Corporation). This previous research discounted
the possibility that the effect of CTC-96 is due to toxicity
by evaluating the effects of CTC-96 both in tissue culture
[5–500 ug/ml (no toxicity ≤50 ug/ml, trace and transient
at 100 ug/ml): Vero (African Green monkey kidney
fibroblast cell line), HeLa (human cervical cancer cell
line), A549 (human alveolar carcinoma cell line), SIRC
(immortalized rabbit corneal epithelial cell line) and
HeP2 (human laryngeal squamous cancer cell line)[5-8]
and unpublished observations] and systemic applications
(IP and IV) in mice (unpublished observations), as well as
via topical administration of 20 ul drops 3x, 4x, 5x, 6x and
9x/day on normal uninfected rabbit (New Zealand White
rabbits) eyes [total of 240 eyes,10–500 ug/ml, checkedBMC Ophthalmology 2006, 6:22 http://www.biomedcentral.com/1471-2415/6/22
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clinically and histologically[7] (and unpublished observa-
tions)] although it is still possible that diseased eyes may
be more sensitive than normal ones. Phase II studies for
the treatment of HSV-1 are presently underway.
There is a noticeable difference in the efficacious dose
against Adenovirus than that against Herpesvirus, where
concentrations as low as 5 ug/ml were found to possess
strong antiviral activity in vitro[7] and in rabbit eyes with
an IC50 for HSV-1 in vitroof 0.7 ug/ml (Winicov, Redox
unpublished observations). Current findings on human
Adenovirus type 5 (Ad-5) demonstrated that a concentra-
tion of 50 ug/ml of CTC-96 is required to obtain full anti-
viral efficacy. We attribute at least part of this difference to
the effect of the drug on membrane proteins of enveloped
viruses (e.g. HSV-1 and HIV) rather than capsid or intra-
capsid proteins. CTC-96 interacts with a membrane glyco-
protein of HIV that results in virus inactivation (in prepa-
ration). Since Adenovirus does not possess a membrane,
it is possible that the inhibitory action of the drug involves
binding to one or more capsid or intra-capsid proteins
that are less accessible to the drug than membrane surface
proteins in enveloped viruses.
Thus, CTC-96 has a completely different mode of action
than nucleotide analogs as well as other DNA replication
inhibitors. The virucidal effect of CTC-96 can be due to
various modes of action of the drug, but the major activity
of the drug entails disruption of protein conformation
through binding to methyl imidazole nitrogens of specific
histidines in several protein types[31]. But the compound
is also known to be a superoxide scavenger[32] (and
unpublished data: Redox Pharmaceutical Corporation).
In conclusion, the corneal and conjunctival scarification
method of adenovirus infection has proven to be a usable
model of ocular Ad-5 infection in the rabbit as it approxi-
mates the signs and symptoms of adenvirus-derived con-
junctivitis in human eyes. In addition, topical CTC-96 has
demonstrated significant anti-viral activity against human
adenovirus type 5 (Ad-5) in these in vivo models both by
clinical examination and viral plaque assays.
Clearly more studies will be needed to evaluate com-
pletely the efficacy and safety of CTC-96 and clinical trials
in humans will be necessary to determine the safety and
efficacy of CTC-96 for treating human adenoviral kerato-
conjunctivitis.
Conclusion
I. In vitro studies
A. No toxic effects observed in HeLa, A549 or SIRC cells
for CTC-96 at the therapeutic concentration of 10 ug/ml.
B. CTC-96 demonstrated virucidal activity against Adeno-
virus type 5 in tissue culture with HeLa, A549 and SIRC
cell lines.
1. In all cases, peak efficacy was observed in concentra-
tions  ≥ 50 µg/ml, while lower concentrations showed
decreasing dose-responsiveness.
2. Greater viral replication/yield and antiviral activity was
observed in HeLa >A549 > SIRC.
II. Animal studies
A. In the Model Development experimentation (testing of the method 
of infection)
1. Infection via corneal and conjunctival scarification
method (Group "CC") produced a conjunctival infection
with occasional keratitis similar to human disease.
2. The corneal injection method (Group "CI") yielded pri-
marily stromal involvement.
3. The conjunctival scarification method (Group "C") did
not consistently produce acute conjunctivitis.
4. The conjunctival scarification method (Group "C") did
not produce any keratitis.
B. In the CTC Efficacy experimentation (testing of the efficacy of 
human adenovirus type 5 in a NZW rabbit model)
1. Conjunctivitis was seen in all eyes by day 8 post-infec-
tion.
2. Resolution was fastest in treatment group "50/9" where
most animals resolved by Day 21 post-treatment initia-
tion (pti):
"50/9" ≈ "50/6" > "25/6" > "-".
2. The efficacy of CTC-96 in treatment group A50/6" was
not statistically less effective than that observed in treat-
ment group A50/9": most animals resolving by Day 21
pti.
3. The degree of severity of the conjunctiva was lower in
all treatment groups as compared to the control eyes.
4. Little corneal or intra-ocular changes were noted in any
of the treatment groups.
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